经口手术治疗HPV阳性原发不明鳞癌的长期结局
本研究回顾2001至2012年接受经口手术、颈淋巴结清扫及风险导向辅助治疗的HPV相关原发不明口咽癌患者,随访中位13.0年。10年总生存、疾病特异性生存和无病生存分别为87.7%、96.7%和91.7%,长期结局优良,少数患者出现头颈部第二原发癌。
要点
- 经口手术联合颈清扫及风险导向辅助治疗可获得优良长期生存。
- 10年总生存87.7%,疾病特异性生存96.7%,无病生存91.7%。
- 7例(10.9%)发生头颈部第二原发癌,平均于初治后9.23年出现。
核心结论
- 经口手术、颈淋巴结清扫及风险导向辅助治疗用于HPV阳性原发不明癌,长期总生存、疾病特异性生存和无病生存均优良。
- 少数患者仍会发生头颈部第二原发癌,需长期随访。
研究设计与样本
- 回顾性队列研究,纳入2001至2012年在本学术医疗中心接受经口手术治疗的HPV相关原发不明口咽癌患者。
- 复习人口学资料、吸烟史、分期、辅助治疗、疾病状态及挽救治疗,并用Kaplan-Meier法估算生存。
- 第二原发头颈部癌定义为非HPV相关黏膜病变、不同亚部位的HPV相关病变或治疗5年及以上后出现的病变。
主要发现
- 总生存计算的中位随访时间为13.0年。
- 10年总生存率为87.7%(95%CI 79.9%-96.7%)。
- 10年疾病特异性生存率为96.7%(95%CI 92.2%-100%)。
- 10年无病生存率为91.7%(95%CI 84.9%-99.0%)。
- 15例死亡中仅2例明确与原发癌相关;4例在5年内复发;7例(10.9%)发生头颈部第二原发癌,平均于初治后9.23年出现,其中3例为HPV阳性。
临床怎么用
- 对HPV阳性原发不明口咽癌,经口手术联合颈清扫及风险导向辅助治疗可作为识别原发灶并减少咽部放疗的有效策略。
- 治疗后应长期随访,关注头颈部第二原发癌,原文中第二原发癌平均出现于初治后9.23年。
局限性
- 为单中心回顾性队列研究,样本来自学术医疗中心。
- 第二原发癌定义包含多种情况,原文未报告其发生率的置信区间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Transoral surgery with neck dissection and risk-directed adjuvant therapy for unknown primary HPV-associated squamous cell carcinoma is an effective strategy to identify the primary lesion, minimize radiation dose to the pharynx, and obviate the need for chemotherapy and/or radiation, but late survival outcomes and the development of second primary head and neck (HN) mucosal primaries have not been well described. STUDY DESIGN: Retrospective cohort study of HPV associated unknown primary oropharynx cancer treated with transoral surgery between 2001 and 2012 was performed. SETTING: Academic medical center. METHODS: Demographics, smoking history, staging, adjuvant therapy, disease status, and salvage therapy were reviewed. Kaplan-Meier estimates for disease-free, disease-specific, and overall survival were calculated. Second HN primaries were defined as mucosal lesions that were not HPV-associated, HPV-associated at a different subsite, or emerging 5 or more years after treatment. RESULTS: With a median follow-up for overall survival calculations of 13.0 years, overall survival, disease-specific, and disease-free survival estimates at 10 years were 87.7% (95% CI 79.9%-96.7%), 96.7% (92.2%-100%), and 91.7% (84.9%-99.0%), respectively. Of 15 deaths, only 2 were definitely related to the original cancer. Four patients had a recurrence within 5 years. Seven patients (10.9%) developed a second primary in the head and neck a mean 9.23 years after initial treatment, 3 of which were HPV+. CONCLUSION: Long-term overall, disease-specific, and disease-free survival for patients with HPV+ unknown primary carcinomas treated with transoral surgery, neck dissection, and risk-directed adjuvant therapy are excellent. A minority will develop second primaries HN cancers.
引用
- Barrett TF, Boukind A, Enin K, et al. Long-Term Outcomes of Patients With HPV+ Unknown Primary Squamous Cell Carcinoma Treated With Transoral Surgery. Otolaryngol Head Neck Surg. 2025. PMID: 41031644. doi:10.1002/ohn.70029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。